Background: There are limited data on treatment outcomes in the growing population of elderly patients with locally recurrent/metastatic breast cancer (LR/mBC). To gain information on first-line bevacizumab combined with chemotherapy in the elderly, we analyzed data from the ATHENA trial in routine oncology practice.
introduction
In patients with human epidermal growth factor receptor-2 (HER2)-negative locally recurrent or metastatic breast cancer (LR/mBC), the efficacy of first-line chemotherapy can be significantly improved through combination with the antivascular endothelial growth factor monoclonal antibody bevacizumab, as demonstrated in three randomized phase III trials [1] [2] [3] . Findings from the E2100 trial evaluating first-line weekly paclitaxel with or without bevacizumab [1, 4] were substantiated in the AVADO trial, which evaluated docetaxel combined with bevacizumab [2] , and the RIBBON-1 trial, which investigated taxane monotherapy, anthracycline-based combination therapy or capecitabine monotherapy combined with bevacizumab [3] . In all three trials, both progression-free survival (PFS; the primary end point) and response rate were significantly superior with bevacizumab-containing therapy versus chemotherapy alone. Importantly, improved efficacy was achieved with a limited impact on the safety profile of chemotherapy.
The open-label international ATHENA study (n = 2251) [5] was designed specifically to evaluate the safety of first-line bevacizumab combined with standard (non-anthracycline) chemotherapy. The choice of chemotherapy regimen and schedule was at the investigator's discretion and there were fewer exclusion criteria: in particular, patients with Eastern Cooperative Oncology Group performance status (ECOG PS) 2 were eligible. These features of the trial led to enrollment of a broader patient population more representative of routine oncology practice than randomized phase III trials.
Age and comorbidities are among the factors most strongly influencing treatment choice in patients with breast cancer [6, 7] , yet older patients are typically underrepresented or excluded in clinical trials [8, 9] . Consequently, optimal treatment approaches for these patients are poorly defined [10] . There is evidence that elderly women with breast cancer are not always given the most effective treatment [8, [11] [12] [13] [14] , but without data specifically in older patients, the validity of extrapolating findings derived primarily from younger populations is questionable.
Subpopulation analyses of the phase III trials of first-line bevacizumab-containing therapy have been carried out to determine the impact of bevacizumab in clinically relevant subgroups, including the elderly. In E2100, subpopulation analyses suggested that the effect of bevacizumab declined significantly with age treated as a continuous variable (P = 0.04) [1] . Nevertheless, the PFS hazard ratio (HR) of 0.67 in 167 patients ‡65 years strongly favored the bevacizumabcontaining arm (median 10.4 versus 6.1 months with paclitaxel alone) [15] . Subpopulation analyses of AVADO and RIBBON-1 suggested similar PFS benefits in older patients [16] . In the AVADO trial, the HR in patients ‡65 years (n = 86) was 0.68 favoring bevacizumab 15 mg/kg combined with docetaxel (median 10.3 versus 7.7 months in the placebo-docetaxel arm). In RIBBON-1, patients in one of the two cohorts received bevacizumab combined with capecitabine, which may be particularly relevant in older patients. The HR in patients ‡65 years was 0.69, identical to that in the overall population [16] . Median PFS with bevacizumab-capecitabine was 9.1 months in the older subgroup versus 8.6 months in patients <65 years [17] .
While the efficacy of first-line bevacizumab-containing therapy has been investigated to some extent through such subpopulation analyses, there is very limited safety information in older LR/mBC patients. To provide better understanding of the safety and efficacy of first-line bevacizumab-containing therapy in older patients treated in everyday practice, we conducted a subpopulation analysis of the ATHENA trial.
patients and methods
The methodology of the ATHENA trial has been described in detail previously [5] . In brief, patients aged ‡18 years with ECOG PS £2 received bevacizumab (10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks, depending on chemotherapy schedule) combined with taxane-based chemotherapy as first-line treatment of HER2-negative LR/mBC. If taxanes were contraindicated or not the physician's preference, bevacizumab could be combined with alternative standard chemotherapy, excluding anthracycline-based regimens. Treatment was continued until disease progression, unacceptable toxicity, clinical judgment to discontinue, or withdrawal of consent.
The primary objective was to assess the safety profile of bevacizumab combined with first-line chemotherapy. Efficacy was a secondary end point. Subpopulation analyses according to age were prespecified in the statistical analysis plan. All patients provided written informed consent before undergoing study-specific procedures. The study design and conduct and the informed consent document were approved by independent ethics committees.
results

patient population
The trial included 2251 patients, of whom 175 (7.8%) were ‡70 years, 51 (2.3%) were ‡75 years, and 7 (0.3%) were ‡80 years of age. In our analysis, we chose a cut-off of ‡70 years; in this subpopulation, the median age was 73 years. Table 1 shows baseline characteristics in older versus younger patients. As expected, estrogen receptor (ER)-positive disease and/or disease-free interval >24 months were more common in older patients and adjuvant chemotherapy and PS 0 were less common. Cardiovascular comorbidities were reported more frequently in older than in younger patients, driven by hypertension and dyslipidemia. Other cardiovascular comorbidities were evenly distributed between the two subgroups (data not shown).
To obtain an indication of comorbidities in each of the subgroups, the number of active disease classes at baseline was calculated. The number of disease classes rather than individual comorbidities was chosen as a more robust indicator as patients with, for example, numerous related cardiovascular comorbidities would otherwise be classified as having more comorbidities than patients with several distinct comorbid conditions. Although this figure does not provide comprehensive information on comorbidities, it is the best available indicator from the data collected in the ATHENA study. At baseline, 73% of patients ‡70 years and 43% of those <70 years had comorbid conditions, with a median of one disease class in each group (range 1-5 versus 1-6, respectively). The median number of cardiovascular comorbidities was one in both groups (range 1-3 versus 1-6, respectively).
treatment exposure
Among patients ‡70 years, almost half (46%) received paclitaxel monotherapy with bevacizumab. In the remaining patients ‡70 years, bevacizumab was combined with docetaxel monotherapy (27%), vinorelbine monotherapy (6%), taxanecontaining combination chemotherapy (5%), capecitabine monotherapy (3%), non-taxane combination chemotherapy (2%), other monotherapy (1%), or the chemotherapy regimen was changed before disease progression (11%). Sixteen of the 19 patients who switched chemotherapy before progression initially received a taxane (docetaxel in 11 patients; paclitaxel in 5), either as monotherapy (n = 9) or with another chemotherapy (n = 7). Overall, these 19 patients had little impact on the proportions of patients in each chemotherapy subgroup. Generally, the percentages of patients receiving each class of chemotherapy were similar to the younger subgroup, although in older patients bevacizumab was combined more often with paclitaxel and less often with taxane-containing doublets.
The median duration of follow-up was 12.6 months (range 0.1-27.4) in the subgroup of patients ‡70 years and 12.8 months (range 0.0-31.1) in those <70 years. The median duration of bevacizumab therapy was 5.9 months in the older subgroup versus 6.2 months in patients aged <70 years. Corresponding values for median duration of chemotherapy were 3.6 and 4.2 months, respectively. Figure 1 shows bevacizumab and chemotherapy exposure according to chemotherapy partner.
At the time of data cut-off, bevacizumab had been discontinued in 156 patients (89%) ‡70 years. Of these, 18 (12%) were still receiving chemotherapy at the time of bevacizumab discontinuation (versus 10% of those aged <70 years). The most common reasons for discontinuing bevacizumab were progressive disease (51%), adverse events Annals of Oncology original articles (23%), or other reasons (15%). The proportion discontinuing bevacizumab for adverse events was slightly higher than in patients <70 years (23% versus 15%, respectively); conversely, in the younger subgroup, 64% of patients discontinued bevacizumab because of disease progression (versus 51% of older patients). Focusing specifically on adverse events that we assumed could lead to bevacizumab discontinuation more commonly in older patients, we observed an approximate doubling in the older subgroup. Bevacizumab was discontinued in the ‡70 versus <70 subgroups for arterial thromboembolism (ATE) or venous thromboembolism (VTE) in 2.9% versus 1.8% of patients, respectively; for congestive heart failure in 0.6% versus 0.3%, respectively; and for hypertension in 2.9% versus 1.8%, respectively. Discontinuations because of withdrawal of consent, protocol violation, loss to follow-up, and completion of planned treatment regimen were similarly infrequent in the two subgroups (data not shown).
safety
Grade ‡3 adverse events occurred in 60% of patients aged ‡70 years and 54% of those aged <70 years ( Table 2 ). The most frequently reported grade ‡3 adverse events in patients ‡70 years were decreased neutrophil count (13%), fatigue (9%), and decreased white blood cell count (9%). In the younger cohort, decreased neutrophil count (15%), decreased white blood cell count (10%), and febrile neutropenia (5%) were the most common grade ‡3 adverse events. Toxic effects resulted in death in 9 patients (5.1%) aged ‡70 years and 62 patients (3.0%) aged <70 years. Among the older group, these events (irrespective of relationship to treatment) consisted of two cases of metabolic acidosis and one case each of cardiopulmonary failure, myocardial infarction, neutropenic sepsis, pneumonia, disseminated intravascular coagulation, general physical health deterioration, and a fall. None of these deaths was considered attributable to bevacizumab [compared with five deaths (0.2%) in the younger subgroup].
Data on adverse events of special interest (previously reported in bevacizumab clinical trials) were collected for 6 months after completion of bevacizumab therapy and are summarized in Table 3 . The only grade ‡3 adverse events of special interest occurring in notably more patients ‡70 years than in the younger subgroup were hypertension and proteinuria. The majority of cases of hypertension were grade 3. There were no cases of gastrointestinal perforation in the older subgroup and no excess of ATE/VTE in older compared with younger patients.
To try to determine whether the risk of hypertension in older patients correlated with presence and severity of baseline hypertension, we conducted further exploratory analyses. Hypertension was more common in patients with active hypertension at baseline than in those without (48% versus 37%, respectively, in patients ‡70 years; 38% versus 26%, respectively, in patients <70 years). As information on baseline severity of hypertension was not collected in the ATHENA trial, baseline medical history, laboratory results, blood pressure, and antihypertensive comedications for each patient with active hypertension were assessed by a cardiologist, who assigned a baseline hypertension grade for each individual according to European guidelines [18] . According to this review, baseline hypertension in the older subgroup was grade 0 in 90 patients (51%), grade 1 in 64 patients (37%), grade 2 in 18 patients (10%), and grade 3 in 3 patients (2%). There was no apparent relationship between the presence or severity of baseline hypertension and severity of hypertension during bevacizumabcontaining therapy. The lack of relationship could not be explained by substantial differences in the duration of bevacizumab treatment [median 6.4 months (range 0-21.3) in those with grade 0, 5.4 months (range 0-26.5) in those with grade 1, and 5.4 months (range 0-18.1) in those with grade 2-3 at baseline]. To explore a possible relationship further, we expanded the analysis population to include all patients aged ‡65 years (n = 377). As shown in Table 4 , there was a higher incidence of hypertension during the study among patients original articles Annals of Oncology with baseline hypertension than in those without (47% versus 39%, respectively). However, Fisher's exact test revealed no statistically significant relationship between baseline hypertension (any grade) and hypertension during the study (any grade) (P = 0.141). To determine whether the severity of baseline hypertension was related to the severity of hypertension during bevacizumab-containing treatment, the data were analyzed by Spearman's rank correlation. No significant correlation was observed [r = 0.054, 95% confidence interval (CI) 20.046 to 0.155; P = 0.291]. Similarly, Spearman's rank correlation showed no significant relationship between the severity of baseline hypertension and the number of occurrences of hypertension of any grade during study therapy (r = 0.055, 95% CI 20.046 to 0.156; P = 0.283).
In both age groups, we observed a slightly higher incidence of hypertension among patients receiving bevacizumab combined with paclitaxel compared with non-paclitaxel-containing regimens (48% versus 36%, respectively, in patients ‡70 years; 31% versus 26%, respectively, in those <70 years).
Among the elderly population, analysis of safety according to ECOG PS suggested a similar incidence of grade ‡3 adverse events in patients with ECOG PS 0 (42 of 71 patients; 59%) compared with ECOG PS 1/2 (62 of 103 patients; 60%). Similar comparison of adverse events of special interest (previously associated with bevacizumab in clinical trials) revealed no major differences in incidence according to ECOG PS, except for grade ‡3 hypertension (10% versus 5%, respectively).
efficacy
Median time to progression was 10.4 months (95% CI 8.8-11.8 months) in the subgroup of patients ‡70 years. The overall response rate was 42%. At the time of data cut-off, 36.0% of patients ‡70 years versus 27.3% of those <70 years had died. The majority of deaths in both subgroups were from breast cancer (29.7% versus 23.9%, respectively). Non-disease-related causes of death in the elderly subgroup consisted of concurrent illness (2.3%), toxicity of chemotherapy (1.1%), general health deterioration, Alzheimer's disease, myocardial infarction, a fall, and unknown cause [one case of each (0.6%)]. Overall survival data are immature.
discussion
Limited data exist on the efficacy and safety of biological agents in elderly patients with advanced breast cancer. Randomized phase III trials typically enroll very few older patients, often because of strict inclusion criteria and a relatively low upper age limit. In addition, strictly defined chemotherapy (agent, dose, and schedule) may deter clinicians from enrolling elderly or less fit patients into clinical trials. In ATHENA, the choice of chemotherapy agent, dose, and schedule was at the investigator's discretion, potentially providing a more accurate reflection of clinical practice in elderly or less fit patients. Our analyses represent the first report of treatment effect with bevacizumab in LR/mBC patients aged ‡70 years. We consider this to be a more acceptable age cut-off for defining elderly patients than the frequently selected age of 65 years. Data from 
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the United States indicate that the median age at cancer diagnosis is 67 years and almost 30% of new cancer diagnoses are in patients aged ‡75 years [19] . The ATHENA study population of >2000 patients enabled robust assessment of safety and efficacy in the elderly. Findings from our analyses suggest that bevacizumabcontaining therapy is effective and well tolerated in patients aged ‡70 years. Although toxic effects were fatal in 5.1% of patients, none of these deaths was considered to be related to bevacizumab therapy. Nevertheless, it is clear that elderly patients should be treated with caution. Selection of the most appropriate chemotherapy is important, and awareness and monitoring of chemotherapy-related adverse effects, which could potentially be exacerbated by bevacizumab, are particularly important in this population. Hypertension and proteinuria were the only grade ‡3 bevacizumab-related adverse events reported more frequently in patients ‡70 than in those <70 years old. We attempted to identify potential correlations between baseline comorbidities and safety of bevacizumabcontaining therapy. In particular, although the incidence of hypertension during the study appeared higher in patients with active baseline hypertension, we found no relationship between presence or severity of baseline hypertension and occurrence or severity of hypertension with bevacizumab. Likewise, expansion of the elderly subgroup to include all patients ‡65 years revealed no correlation. Therefore, we do not consider presence of hypertension in elderly patients to be a reason for excluding bevacizumab in these patients.
Except for hypertension and proteinuria, there was no increase in grade ‡3 adverse events of special interest in patients ‡70 years. Notably, there was no excess of grade ‡3 ATE/VTE, conflicting with findings from analyses across tumor types or specifically in colorectal cancer, which suggested increased risk in elderly patients [20] [21] [22] . Interestingly, bevacizumab was discontinued for ATE/VTE in 2.9% of patients ‡70 years, yet occurred at grade ‡3 in only 0.6% during bevacizumab-containing treatment, suggesting that bevacizumab was discontinued for grade 1 or 2 events. Corresponding figures in those aged <70 years were 1.8% and 1.2%. Therefore, it appears that the higher discontinuation rate for ATE/VTE reflects a more conservative approach by clinicians treating elderly patients rather than an increased incidence during bevacizumab therapy. Safety observations from our trial are generally consistent with a similar subpopulation analysis of elderly colorectal cancer patients treated in the BRiTE observational study [21] , except for tumor-specific differences in the safety profile of bevacizumab (e.g. increased incidence of gastrointestinal perforation in colorectal cancer patients).
There was no evidence of poorer efficacy in the older subgroup of patients compared with the overall population [5] , although potential effects may not have been detected in this relatively small subgroup. Conclusions on the relative efficacy in younger and older patients cannot be drawn because of the retrospective nature of these analyses, differences in baseline characteristics (e.g. ER status, disease-free interval), and differences in chemotherapy partner (and potentially doses and schedules). Subpopulation analyses of AVADO [23] and RIBBON-1 [17] suggested that all patient subpopulations, including elderly patients, benefited from combining bevacizumab with first-line chemotherapy. However, no prospective randomized data are available specifically in older patients with mBC.
A strength of the present analysis is the broad patient population included in ATHENA. Eligibility criteria were less restrictive than in randomized trials and therefore the data are more representative of real-life oncology practice. However, we recognize that careful selection of patients for ATHENA, particularly among older patients, may lead to some bias, which cannot be neglected when extrapolating our findings to everyday practice.
A limitation of our analysis is the lack of a chemotherapyalone control arm, preventing assessment of the impact of combining bevacizumab with chemotherapy in older patients. However, this is arguably less important for assessment of tolerability and feasibility than determination of efficacy benefit. A second weakness is the use of chronological age ‡70 years rather than biological age, which has a greater impact on treatment decisions in elderly patients. No specific geriatric assessment was included in the ATHENA trial but would have added valuable information when assessing treatment in elderly patients. Thirdly, information on the severity of baseline hypertension was slightly limited. We attempted to overcome this through detailed case-by-case review and classification according to published guidelines, enabling detailed analysis of hypertension. Finally, although the analysis population is reasonably large (n = 175), it is possible that subtle effects on tolerability and efficacy were not detected.
Despite these limitations, our retrospective analysis of 175 patients ‡70 years provides much-needed information on the tolerability and activity of bevacizumab-containing therapy in elderly breast cancer patients. Based on these results, we consider that older age should not preclude use of bevacizumab in patients with LR/mBC, even in patients with controlled hypertension. A prospective single-arm study by the South Eastern European Research Group evaluating first-line bevacizumab combined with capecitabine specifically in patients ‡70 years has started recruitment and will provide further data on this important issue.
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Grade of hypertension at baseline 0 (absent; n = 216) 1 (n = 124) 2 (n = 33) 3 (n = 4)
Any hypertension during the study, n (%) 84 (38. 
